The Effect of Anti-Scl-70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis.
Bochra JandaliGloria A SalazarMarie HudsonMarvin J FritzlerMarka A LyonsRosa M Estrada-Y-MartinJulio CharlesKatherine A TerracinaMaureen D MayesShervin AssassiPublished in: ACR open rheumatology (2022)
Anti-Scl-70 antibodies determined by ID predicted faster FVC decline in patients with SSc-related ILD. Notably, both CIA and LIA for the same antibody did not predict rate of FVC decline at their current cutoffs of positivity. The discrepancy observed between anti-Scl-70 antibody assays can have relevant implications for clinical care and trial enrichment strategies in SSc-ILD.